Photo taken from Benedetta Pellegrino/X
Jul 9, 2024, 22:15
Benedetta Pellegrino: Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1
Benedetta Pellegrino, Resident in Medical Oncology at the University Hospital of Parma, shared on X:
“Discover our latest study on the validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1 in breast and ovarian cancer! ”
Read further.
Source: Benedetta Pellegrino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38